Ticker Launch
Sign inTry it free

IPO · ALMS

Alumis Inc.

Formerly FL2021-001, Inc.

Alumis Inc. (ALMS) priced its initial public offering on Jun 28, 2024 at $16.00 per share, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $829.5M. Morgan Stanley was lead-left underwriter, joined by Leerink Partners, Cantor and Guggenheim. Cooley advised the company and Latham & Watkins advised the underwriters.

ALUMIS INC. is a clinical-stage biopharmaceutical company developing two TYK2 inhibitors: ESK-001, a second-generation inhibitor, and A-005, a central nervous system-penetrant molecule intended for neuroinflammatory and neurodegenerative diseases such as multiple sclerosis.

Status
IPO
Ticker
ALMS
Exchange
Nasdaq Global Select
Priced
Jun 28, 2024
IPO price
$16.00
Market cap at IPO price
$829.5M
First filed
Jun 7, 2024
Underwriters
Morgan Stanley, Leerink Partners, Cantor and Guggenheim
Company counsel
Cooley
Underwriters' counsel
Latham & Watkins
Sector
Biotech & pharma
Country / state
CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.

More on this listing for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other Biotech & pharma IPOs in 2024